Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.
Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P = .006) and larger postoperative tumor diameters (7.26 vs 6.21; P = .033).
Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076